Metotrexato nell'artrosi infiammatoria erosiva della mano (MERINO)
Lo studio MERINO (Metotrexato nell'osteoartrite infiammatoria erosiva): uno studio randomizzato controllato con placebo per valutare l'efficacia clinica e la sicurezza del metotrexato nell'osteoartrite infiammatoria erosiva della mano.
A placebo-controlled randomized controlled trial exploring the effect of methotrexate on pain, function and structural outcomes in erosive inflammatory hand osteoarthritis.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
The trial will include Norwegian adult males and females with symptomatic erosive inflammatory hand osteoarthritis.
Participants will be randomized 1:1 to either:
- Methotrexate oral x 1/week; weekly starting dose 15 mg for two weeks, followed by 20 mg the remaining weeks (intervention group). Dosage can be reduced to as low as 10 mg if higher doses are not tolerated.
- Placebo (control group).
Both arms will receive folic acid 1mg daily.
The treatment duration for both groups is 52 weeks.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 4
Contatti e Sedi
Luoghi di studio
-
-
-
Oslo, Norvegia
- Diakonhjemmet Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Finger joint pain 40-80 on 0-100 visual analog scale (VAS) with insufficient pain relief from, inability to tolerate or contra-indications to oral paracetamol and/or NSAIDs, and hand symptoms (pain, aching, or stiffness) on most days the previous 6 weeks before randomization.
- Hand OA according to the American College of Rheumatology (ACR) criteria, at least 1 distal (DIP) or proximal interphalangeal (PIP) joint of the 2nd-5th finger with radiographic pre-erosive (J-phase) or erosive disease (E-phase) according to the Verbruggen-Veys anatomical phase system, and at least two DIP/PIP joints with power Doppler signal of at least grade 1 or grey-scale synovitis of at least grade 2 on ultrasound.
Exclusion Criteria:
A full list of the exclusion criteria for this study comprised the following:
-
Contraindications to methotrexate:
- Abnormal renal function, defined as serum creatinine >142 µmol/L in women and >168 µmol/L in men, or a glomeruli filtration rate (GFR) <40 mL/min/1.73 m2.
- Abnormal liver function, defined as transaminases above the upper normal limit, active or previous hepatitis B or C infection, or known cirrhosis
- Lung fibrosis (maximum 6 months old x-ray), active infection, or reduced hematopoiesis (i.e. anemia, leukopenia and/or thrombocytopenia).
- Planned pregnancy within 18 months after screening (men/women), and pregnancy, breastfeeding, or insufficient anti-conception therapy for female fertile participants. Contraception should be maintained during treatment and until the end of systemic exposure, i.e. 3 months after methotrexate discontinuation. Sufficient anti-conception therapy consists of intra-uterine device (coil) or hormonal anti-conception (birth control pills, implant, intra-uterine system, dermal patch, vaginal ring, or injections).
- Alcohol or other drug abuse in the last year.
- Intolerance to lactose.
-
Chronic inflammatory rheumatic diseases (such as rheumatoid arthritis and psoriatic arthritis or gout), active inflammatory bowel disease, or positive rheumatoid factor or anti-CCP antibodies.
-
Other severe co-morbidities such as hemochromatosis, fibromyalgia, psoriasis, blood dyscrasias, and coagulation disorders, history of malignancy (except successfully treated squamous or basal cell skin carcinoma), uncontrolled diabetes mellitus, severe hypertension, unstable ischemic heart disease, severe heart failure, severe pulmonary disease, severe and/or opportunistic infections and/or chronic infections, active tuberculosis, positive human immunodeficiency virus (HIV) status, recent stroke, bone marrow hypoplasia, or demyelinating diseases of the central nervous system.
-
Other likely causes of hand symptoms: thoracic outlet syndrome, carpal tunnel disease, diabetic cheiropathy, injury in finger joints previous 6 months, or palmar tenosynovitis/trigger finger.
-
Oral or intra-muscular steroids in the previous month
-
Intra-articular treatments or aspirations of any kind of any joint in the hands 3 months before inclusion
-
Analgesics or NSAIDs, unless stable dosage for ≥1 month.
-
Symptomatic slow-acting drugs for OA (SYSADOA), unless stable dose for ≥3 months and require stable dose throughout the study.
-
Disease-modifying osteoarthritis drugs (DMOADs) previous three months.
-
Scheduled hand surgery during study participation.
-
Planning to start other treatments for hand OA in the study participation period.
-
Not able to adhere to the study visit schedule and protocol requirements.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore attivo: Methotrexate
Methotrexate oral x 1/week; weekly starting dose 15 mg for two weeks, followed by 20 mg the remaining weeks. Additional Folic acid 1mg prescribed daily. |
Methotrexate 2.5mg oral tablet. Folic acid |
|
Comparatore placebo: Placebo
3 capsules per week for two weeks, followed by 4 capsules the remaining weeks. Additional Folic acid 1mg prescribed daily. |
Placebo capsule Folic acid |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Finger pain on a visual analogue scale
Lasso di tempo: 6 months
|
Difference in self-reported finger joint pain previous 48 hours on a 0-100 mm scale at 6 months of treatment; higher value indicate worse outcome. |
6 months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Finger pain on a visual analogue scale
Lasso di tempo: Month 1, 3, 9 and 12.
|
Self-reported finger pain previous 48 hours on a 0-100 mm scale; higher value indicate worse outcome. |
Month 1, 3, 9 and 12.
|
|
Thumb pain on a visual analogue scale
Lasso di tempo: Month 1, 3, 6, 9 and 12.
|
Self-reported thumb pain previous 48 hours on a 0-100 mm scale; higher value indicate worse outcome. |
Month 1, 3, 6, 9 and 12.
|
|
Pain most painful finger joint on a visual analogue scale
Lasso di tempo: Month 1, 3, 6, 9 and 12.
|
Pain most painful finger joint last 48 hours on a 0-100 mm scale; higher value indicate worse outcome. |
Month 1, 3, 6, 9 and 12.
|
|
Patient-reported disease activity on a visual analogue scale
Lasso di tempo: Month 1, 3, 6, 9 and 12.
|
Patient-reported disease activity last 48 hours on a 0-100 mm scale; higher value indicate worse outcome. |
Month 1, 3, 6, 9 and 12.
|
|
Pain all joints on a visual analogue scale
Lasso di tempo: Month 1, 3, 6, 9 and 12.
|
Pain all joints last 48 hours on a 0-100 mm scale; higher value indicate worse outcome. |
Month 1, 3, 6, 9 and 12.
|
|
Hand diagram pain
Lasso di tempo: Month 6.
|
Finger pain and thumb base pain (yes/no) on hand diagram |
Month 6.
|
|
Body diagram pain
Lasso di tempo: Month 6.
|
Pain in other joints (yes/no) on body diagram |
Month 6.
|
|
AUSCAN
Lasso di tempo: Month 1, 3, 6, 9 and 12.
|
Australian/Canadian hand index (AUSCAN), sum score 0-60, higher value indicate worse outcome. |
Month 1, 3, 6, 9 and 12.
|
|
OMERACT-OARSI responder criteria
Lasso di tempo: Month 1, 3, 6, 9 and 12.
|
Fulfillment of Outcome Measures in Rheumatology Osteoarthritis Research Society International (OMERACT-OARSI) responder criteria. |
Month 1, 3, 6, 9 and 12.
|
|
EQ-5D
Lasso di tempo: Month 1, 3, 6, 9 and 12.
|
Quality-adjusted life years (QALYs) based on the health-related utility scores measured by the generic instrument EuroQol 5 dimensions (EQ-5D), sum score 5-35, higher value indicate worse outcome, in addition to a 0-100 visual analogue scale where higher value indicate better outcome. |
Month 1, 3, 6, 9 and 12.
|
|
MHOQ
Lasso di tempo: Month 6.
|
Michigan Hand Outcomes Questionnaire (MHOQ) pain and physical function subscales; function subscale range 10-50, higher value indicate worse outcome; task subscale range 17-85, higher value indicate worse outcome; work subscale range 5-25, higher value indicate worse outcome; pain subscale range 10-48, higher value indicate better outcome. |
Month 6.
|
|
Grip strength
Lasso di tempo: Month 1, 3, 6, 9 and 12.
|
Grip strength (in kg; using a hand dynamometer) |
Month 1, 3, 6, 9 and 12.
|
|
HOOS-12
Lasso di tempo: Month 6.
|
Hip disability and Osteoarthritis Outcome Score (HOOS)-12, range 12-60, higher value indicate worse outcome. |
Month 6.
|
|
KOOS-12
Lasso di tempo: Month 6.
|
Knee injury and Osteoarthritis Outcome Score (KOOS)-12, range 12-60, higher value indicate worse outcome. |
Month 6.
|
|
Concomitant medication
Lasso di tempo: Month 1, 3, 6, 9 and 12.
|
Concomitant medication |
Month 1, 3, 6, 9 and 12.
|
|
Tender and swollen joints
Lasso di tempo: Month 1, 3, 6, 9 and 12.
|
Number of tender and swollen joints (range 0-30), higher values indicate more affected joints. |
Month 1, 3, 6, 9 and 12.
|
|
Physician-reported disease activity on a visual analogue scale
Lasso di tempo: Month 1, 3, 6, 9 and 12.
|
Patient-reported disease activity on a 0-100 mm scale; higher value indicate worse outcome. |
Month 1, 3, 6, 9 and 12.
|
|
Hand radiographs: Kellgren Lawrence
Lasso di tempo: Month 6 and 12
|
Conventional radiographs: change in radiographic severity according to Kellgren-Lawrence scale, range 0-4 in each joint higher value indicate worse outcome. |
Month 6 and 12
|
|
Hand radiographs: Verbruggen-Veys anatomical phase scoring system
Lasso di tempo: Month 6 and 12
|
Conventional radiographs: radiographic severity in finger joints according to Verbruggen-Veys anatomical phase scoring system, range 1-5; higher value indicate worse outcome. |
Month 6 and 12
|
|
Hand radiographs: OARSI atlas
Lasso di tempo: Month 6 and 12
|
Conventional radiographs: rdiographic severity according to the Osteoarthritis Research Society International (OARSI) atlas for the presence/severity of osteophytes, joint space narrowing and erosions. |
Month 6 and 12
|
|
Hand MRI
Lasso di tempo: Month 6
|
MRI of dominant hand: number of joints with synovitis and BMLs |
Month 6
|
|
Hand ultrasound
Lasso di tempo: Month 1, 3, 6, 9 and 12.
|
Ultrasound: number of finger joints with synovial thickening and power Doppler signals. |
Month 1, 3, 6, 9 and 12.
|
|
Knee ultrasound
Lasso di tempo: Month 6
|
Ultrasound: degree of synovitis in knee joints |
Month 6
|
|
Hip ultrasound
Lasso di tempo: Month 6
|
Ultrasound: degree of synovitis in hip joints |
Month 6
|
|
Adverse events
Lasso di tempo: Through study completion, maximum 12 months, in addition to 3 months after end of treatment.
|
Number of adverse events, serious adverse events, and withdrawals because of adverse events. |
Through study completion, maximum 12 months, in addition to 3 months after end of treatment.
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Sub-study: biopsy of knee OA
Lasso di tempo: Month 6
|
Change in synovial cellular composition and gene expression with single-cell RNA sequencing analyses; subgroup analyses, n=16 patients |
Month 6
|
|
Sub-study: knee pain on a visual analogue scale
Lasso di tempo: Month 6
|
Self-reported knee pain previous 48 hours on a 0-100 mm scale at 6 months of treatment; higher value indicate worse outcome. |
Month 6
|
|
Question about blinding
Lasso di tempo: Month 12
|
The participants are asked which treatment they think they have received |
Month 12
|
|
HADS
Lasso di tempo: Month 6
|
Hospital Anxiety and Depression Scales (HADS), range 0-42, higher value indicate worse outcome. |
Month 6
|
|
PCS
Lasso di tempo: Month 6
|
Pain catastrophizing scale, range 0-12, higher value indicate worse outcome. |
Month 6
|
|
PSQ
Lasso di tempo: Month 6
|
Pain Sensitivity Questionnaire (PSQ), range 0-170, higher value indicate worse outcome. |
Month 6
|
|
Anchor questions for MCII and PASS
Lasso di tempo: Month 6
|
Questions about perceived improvement and acceptable symptom state that will be used to define minimally clinically important improvement and patient acceptable symptom state for other questionnaires |
Month 6
|
|
ASES
Lasso di tempo: Month 6
|
Arthritis Self Efficacy Scale (ASES), range 10-100, higher value indicate better outcome. |
Month 6
|
|
Pain sensitization
Lasso di tempo: Month 6
|
Pain sensitization: Pressure Pain Thresholds (PPT) by digital algometer; temporal summation by punctate probes; Conditioned Pain Modulation (CPM) by blood pressure ischemic test. |
Month 6
|
|
Soluble biomarkers of extracellular matrix turnover
Lasso di tempo: Month 6 and 12
|
Markers of collagen degradation (s-COMP, s-C1M, s-C2M, s-C3M, s-CTX1, sHA), collagen synthesis (s-proC2), aggrecan degradation (s-huARGS) and inflammation (s-calprotectin, s- vimentin, s-hsCRP and s-CRPM); Inflammatory cytokines (IL-1β, IL-1ra, IL-4, IL-6, IL-10, IL-12, IL-17, IL-18, IL-21, IFN-γ, TNF-α, VEGF, GM-CSF, CCL2, CCL3, CCL4, CXCL10) and hormones (leptin and resistin). |
Month 6 and 12
|
|
Omics
Lasso di tempo: Month 6 and 12
|
Omics analyses of whole blood |
Month 6 and 12
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Cattedra di studio: Tore K Kvien, MD, PhD, Professor Em.
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- DIA2020-01
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
The trialists and other study personnel that conceive of the study, and then plan, manage, monitor, analyze and publish it, will have access to IPD. Participants' identification code numbers are de-identified by replacing the original code number with a new random code number. Only the PI and project coordinator have access to this code.
The protocol, SAP, ICF, and CSR will be shared with regulatory agents as required.
Dati/documenti di studio
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .